At the time her salary was negotiated with the board the liquidity landscape for biotechs was different. If history was different, and had the market bid up the price of CHM, they could have done easy raises in a rising share price environment and had decent justification for paying one individual that much money, and she might have still been CEO today.
However the market chose to bid CHM DOWN. To the point of suffocation. So looking at where the company is today, the market has decided the answer is clearly YES, she is too expensive in this point of time. The market has also played a big part in the FUTURE history of CHM, as the intense backroom changes in leadership overlapping with frontline drugs hitting arms, this could instantly become a hot space.
This company is like a person living the highs and lows of a rock n roll superstar!
At the time her salary was negotiated with the board the...
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $17.98M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.2¢ | 2.1¢ | $17.45K | 819.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1138038 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 140000 | 2 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.2¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 2.2¢ | 2.2¢ | 2.1¢ | 486158 | ||
| Last updated 12.42pm 28/05/2024 ? | |||||
| CHM (ASX) Chart |